4 results
To determine the safety and efficacy of coversin in the treatment of patients with PNH resistant to eculizumab.
The primary objective is to determine the effect of co-administration of telepravir, given as 2 tablets of 375 mg every 8 hours and DRV/rtv or fAPV/rtv on the amount of telaprevir and DRV/rtv or fAPV/rtv in the body. The secondary objective is to…
The aim of this study is to collect data in a structured way in order to explore the tolerability, safety and efficacy of paliperiode ER with treatment schedules which will be used in future clinical practice.
* The purpose of this study is to to determine the safety profile of long-termCoversin treatment.* To observe the long term safety and efficacy of Coversin over periods in excess of 6 months* To assess the long term patient acceptability of Coversin…